Trial Profile
Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Nafamostat (Primary)
- Indications Blood coagulation disorders
- Focus Therapeutic Use
- 25 Jun 2015 New trial record